JP Morgan Initiates MAP Pharmaceuticals at Overweight, $23 PT

December 2, 2011 7:15 AM | 7 seconds read |

JP Morgan has initiated coverage on Map Pharmaceuticals MAPP with an Overweight rating and $23 price target.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.